Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 122090 | 14.47 |
09:34 ET | 76082 | 14.255 |
09:36 ET | 109508 | 14.4 |
09:38 ET | 114202 | 14.6397 |
09:39 ET | 125422 | 14.6876 |
09:41 ET | 105272 | 14.505 |
09:43 ET | 56844 | 14.618 |
09:45 ET | 114504 | 14.71 |
09:48 ET | 101636 | 14.5388 |
09:50 ET | 114040 | 14.59 |
09:52 ET | 65583 | 14.44 |
09:54 ET | 119965 | 14.2894 |
09:56 ET | 47750 | 14.3507 |
09:57 ET | 51056 | 14.27 |
09:59 ET | 73646 | 14.28 |
10:01 ET | 63905 | 14.18 |
10:03 ET | 50942 | 14.28 |
10:06 ET | 84891 | 14.15 |
10:08 ET | 73594 | 14.17 |
10:10 ET | 43324 | 14.15 |
10:12 ET | 97215 | 14.1142 |
10:14 ET | 97481 | 14.083 |
10:15 ET | 58205 | 14.145 |
10:17 ET | 39853 | 14.155 |
10:19 ET | 76951 | 14.0449 |
10:21 ET | 33027 | 14.0801 |
10:24 ET | 20497 | 14.085 |
10:26 ET | 42087 | 14.1586 |
10:28 ET | 31431 | 14.195 |
10:30 ET | 56086 | 14.155 |
10:32 ET | 35118 | 14.115 |
10:33 ET | 45641 | 14.15 |
10:35 ET | 14818 | 14.1128 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 2.0B | -4.4x | --- |
PTC Therapeutics Inc | 2.7B | -4.7x | --- |
ACADIA Pharmaceuticals Inc | 2.5B | -1,160.1x | --- |
Azenta Inc | 2.9B | -19.6x | --- |
P3 Health Partners Inc | 197.3M | -1.1x | --- |
Beam Therapeutics Inc | 2.0B | -14.0x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
---|---|
Revenue (TTM) | $996.6M |
Shares Outstanding | 140.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-3.18 |
Book Value | $-5.14 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.